Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?

The treatment strategy of lung cancer with chemotherapy is changing rapidly owing to developments in the characterization of non-small cell lung cancer (NSCLC) genetic profiles and identification of hallmark immunological characteristics (1). Indeed, this represents a time of unprecedented changes occurring within a short period. These advances in knowledge and technologies have led to the development of several targeted therapies and immune checkpoint inhibitors directed against tumor molecules, which also serve as therapeutic biomarkers.